{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1"},{"groupId":"OG001","value":"53.1"},{"groupId":"OG002","value":"29.1"},{"groupId":"OG003","value":"27.3"},{"groupId":"OG004","value":"40.4"},{"groupId":"OG005","value":"39.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Any primary system organ class"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5"},{"groupId":"OG001","value":"26.5"},{"groupId":"OG002","value":"12.7"},{"groupId":"OG003","value":"10.9"},{"groupId":"OG004","value":"19.2"},{"groupId":"OG005","value":"18.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Metabolism and nutrition disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4"},{"groupId":"OG001","value":"18.4"},{"groupId":"OG002","value":"7.3"},{"groupId":"OG003","value":"7.3"},{"groupId":"OG004","value":"12.5"},{"groupId":"OG005","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Gastrointestinal disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2"},{"groupId":"OG001","value":"8.2"},{"groupId":"OG002","value":"3.6"},{"groupId":"OG003","value":"3.6"},{"groupId":"OG004","value":"5.8"},{"groupId":"OG005","value":"5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Investigations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.0"},{"groupId":"OG002","value":"5.5"},{"groupId":"OG003","value":"5.5"},{"groupId":"OG004","value":"3.8"},{"groupId":"OG005","value":"3.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Hepatobiliary disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1"},{"groupId":"OG001","value":"6.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2.9"},{"groupId":"OG005","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Endocrine disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1"},{"groupId":"OG001","value":"4.1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1.9"},{"groupId":"OG005","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Gen disorders,admin site conditions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1.0"},{"groupId":"OG005","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Ear and labyrinth disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1.0"},{"groupId":"OG005","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Infections and infestations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1.0"},{"groupId":"OG005","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Musculoskeletal and connective tissue disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1.0"},{"groupId":"OG005","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Neoplasms benign, malignant and unspecified"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1.0"},{"groupId":"OG005","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Nervous system disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1.8"},{"groupId":"OG003","value":"1.8"},{"groupId":"OG004","value":"1.0"},{"groupId":"OG005","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Psychiatric disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1.8"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1.0"},{"groupId":"OG005","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"title":"Respiratory, thoracic, mediastinal disorders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"104"},{"groupId":"OG005","value":"104"}],"units":"Participants"}],"description":"Only AEs occurring on or after the start of study treatment and no more than 28 days after the discontinuation of study treatment. A patient with multiple occurrences of an AE under one treatment is counted only once in the AE category for that treatment. A patient with multiple severity grades for an AE while on a treatment, is only counted under the maximum grade.","groups":[{"description":"All grades of adverse events. Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \\< 1500 μg /day.","id":"OG000","title":"600 µg Bid - All Grades"},{"description":"Adverse event grades 3 and 4. Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients","id":"OG001","title":"600 μg - Grades 3/4"},{"description":"All grades of adverse events. Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day","id":"OG002","title":"900 μg - All Grades"},{"description":"Adverse event grades 3 and 4. Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg","id":"OG003","title":"900 μg - Grades 3/4"},{"description":"All grades of adverse events for all patients who received 600 µg bid or 900 µg bid of pasireotide sub-cutaneous.","id":"OG004","title":"All Patients - All Grades"},{"description":"All grades of adverse events for all patients who received 600 µg bid or 900 µg bid of pasireotide sub-cutaneous.","id":"OG005","title":"All Patients - Grades 3/4"}],"paramType":"NUMBER","populationDescription":"Three additional arms were created to display subset of subjects with specific criteria.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 256 weeks","title":"Percentage of Patients With a Drug-related Adverse Event That is Recorded as Grade 3 or 4 or as a Serious Adverse Event (SAE)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}